| scholarly article | Q13442814 |
| P356 | DOI | 10.1192/BJP.187.3.229 |
| P698 | PubMed publication ID | 16135859 |
| P50 | author | Eduard Vieta | Q20090640 |
| P2093 | author name string | Michelle Kramer | |
| Mariëlle Eerdekens | |||
| Sumant Khanna | |||
| Benjamin Lyons | |||
| Fred Grossman | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risperidone | Q412443 |
| placebo | Q269829 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 229-234 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | British Journal of Psychiatry | Q4035428 |
| P1476 | title | Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | |
| P478 | volume | 187 |
| Q37326130 | A UK consensus on the administration of aripiprazole for the treatment of mania |
| Q50575578 | A case report using the mental state examination scale (MSES): a tool for measuring change in mental state. |
| Q46495720 | A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone |
| Q35236966 | Acute and long-term treatment of mania. |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q36905879 | Adjunctive treatment of acute mania: a clinical overview |
| Q38154852 | Alternative delivery systems for agents to treat acute agitation: progress to date |
| Q37111491 | Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q38003196 | Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder |
| Q56784033 | Balancing ethical research and placebo administration |
| Q57738604 | Behandlungsmöglichkeiten der akuten Manie mit atypischen Antipsychotika |
| Q33448290 | Bipolar disorder. |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q38211511 | Clinical decision making in the treatment of mixed states |
| Q22252432 | Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania — A systematic review and meta-analysis |
| Q37100104 | Comparison of mania patients suitable for treatment trials versus clinical treatment |
| Q34529810 | Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania |
| Q38586755 | Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder |
| Q36274272 | Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review |
| Q48716278 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania |
| Q38003197 | Efficacy of antimanic treatments in mixed states |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q34994544 | Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q34532071 | Endoxifen, a New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen |
| Q36881398 | Epidemiology, diagnosis and management of mixed mania |
| Q40085552 | Ethical questions in human clinical psychopharmacology: should the focus be on placebo administration? |
| Q53080275 | Factors modifying drug and placebo responses in randomized trials for bipolar mania. |
| Q47314501 | Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study |
| Q43237795 | Indian study sparks debate on the use of placebo in psychiatry trials |
| Q36444742 | Introduction: case studies in the ethics of mental health research |
| Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q33886093 | Long-acting risperidone: a review of its role in the treatment of bipolar disorder |
| Q38833165 | Mixed states in bipolar disorder - changes in DSM-5 and current treatment recommendations |
| Q42252223 | Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection |
| Q36349023 | Pharmacological treatment of mixed states |
| Q36361982 | Polytherapy in bipolar disorder |
| Q43042956 | Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders |
| Q30462823 | Predictive animal models of mania: hits, misses and future directions |
| Q37070490 | Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder |
| Q36648780 | Psychopharmacology of pediatric bipolar disorder: a review |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q35135637 | Research on antipsychotics in India |
| Q37916242 | Research on mood stabilizers in India |
| Q37165588 | Risperidone in the treatment of bipolar mania |
| Q42631462 | Risperidone monotherapy in manic inpatients: an open label, multicentre trial |
| Q36780394 | Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial |
| Q37858609 | Study design and patient characteristics and outcome in acute mania clinical trials |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q37351329 | The ethics of placebo-controlled trials: methodological justifications |
| Q34617315 | The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion |
| Q37429721 | Treating bipolar disorder in the primary care setting: the role of aripiprazole |
| Q36551909 | Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q37973144 | Treatment of mixed bipolar states |
| Q37427122 | Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone |
| Q37852818 | Treatment strategies for dosing the second generation antipsychotics. |
| Q44797813 | Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? |
| Q37416878 | Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice |
| Q51900298 | Validation of a severity threshold for the Mania Rating Scale: a receiver-operating characteristic analysis. |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q46202394 | Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study |
Search more.